Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Sensitivity, Specificity, and Predicted Value01:13

Sensitivity, Specificity, and Predicted Value

In healthcare diagnostics, laboratory tests play a crucial role in identifying and diagnosing a wide range of medical conditions. However, interpreting test results is not always straightforward. An abnormal test result does not always confirm the presence of a disease, just as a normal result does not guarantee its absence. To assess the reliability of these diagnostic tools, healthcare practitioners rely on two key statistical indicators: sensitivity and specificity.
Sensitivity is the...
Positron Emission Tomography01:29

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CDO1 is a new biomarker to discriminate aggressive forms of prostate cancer.

Oncogene·2026
Same author

Robot-assisted versus open surgery for multiple ipsilateral renal tumors: a multicenter matched cohort study (UroCCR-60).

Journal of robotic surgery·2026
Same author

Patient-reported outcomes and experiences in outpatient vs inpatient robot-assisted radical prostatectomy: the BETTY trial.

BJU international·2026
Same author

Results of the Randomized Phase 3 AFU-GETUG-20 Trial Evaluating Adjuvant Leuprorelin Acetate After Radical Prostatectomy in Men with High-risk Localized Prostate Cancer.

European urology oncology·2026
Same author

Digital Systematic Collection of Data for Patient-reported Outcome and Experience Measures Reveals Real-world Recovery Trajectories After Robot-assisted Radical Prostatectomy.

European urology focus·2025
Same author

Impact of intra-abdominal pressure with AirSeal<sup>®</sup> system on patient-reported outcomes and experience measurements after robot-assisted radical prostatectomy.

World journal of urology·2025

Related Experiment Video

Updated: Jun 3, 2026

Standardized SDS-PAGE Workflow for Personalized Protein Corona Profiling in Early Cancer Detection
10:02

Standardized SDS-PAGE Workflow for Personalized Protein Corona Profiling in Early Cancer Detection

Published on: December 19, 2025

Progensa™ PCA3 test for prostate cancer.

Xavier Durand1, Stephane Moutereau, Evanguelos Xylinas

  • 1INSERM U955 Eq7, Henri Mondor University Hospital, Avenue de Lattre de Tassigny, Créteil, France.

Expert Review of Molecular Diagnostics
|March 17, 2011
PubMed
Summary
This summary is machine-generated.

Prostate cancer gene 3 (PCA3) is a superior urinary biomarker for prostate cancer diagnosis compared to PSA. PCA3 testing can help avoid unnecessary repeat biopsies in patients with initial negative results.

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance
05:35

Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance

Published on: June 6, 2025

Related Experiment Videos

Last Updated: Jun 3, 2026

Standardized SDS-PAGE Workflow for Personalized Protein Corona Profiling in Early Cancer Detection
10:02

Standardized SDS-PAGE Workflow for Personalized Protein Corona Profiling in Early Cancer Detection

Published on: December 19, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance
05:35

Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance

Published on: June 6, 2025

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Urology

Background:

  • Traditional prostate cancer diagnostic tools lack accuracy.
  • Prostate cancer gene 3 (PCA3) is a noncoding mRNA overexpressed in prostate tumors.
  • PCA3 shows promise as a urinary biomarker.

Purpose of the Study:

  • To investigate PCA3 as a novel biomarker for prostate cancer.
  • To evaluate the clinical utility of a quantitative PCA3 urine test.
  • To compare PCA3 performance against prostate-specific antigen (PSA).

Main Methods:

  • Demonstrated feasibility of a PCA3 gene-based molecular assay using urine.
  • Developed and utilized the Progensa™ PCA3 urine test.
  • Literature review comparing PCA3 score with PSA predictive value, specificity, and sensitivity.

Main Results:

  • PCA3 is overexpressed in over 95% of primary prostate tumors.
  • The PCA3 urine test is feasible for clinical use.
  • PCA3 score demonstrates superiority over PSA in predictive value and specificity, with slightly lower sensitivity.

Conclusions:

  • PCA3 is a promising urinary biomarker for prostate cancer detection.
  • PCA3 testing can help avoid repeat biopsies in patients with negative initial results.
  • Future research will focus on combining PCA3 with other biomarkers for improved cancer detection and characterization.